HUP0301003A3 - Casein derived peptides and uses thereof in therapy - Google Patents

Casein derived peptides and uses thereof in therapy

Info

Publication number
HUP0301003A3
HUP0301003A3 HU0301003A HUP0301003A HUP0301003A3 HU P0301003 A3 HUP0301003 A3 HU P0301003A3 HU 0301003 A HU0301003 A HU 0301003A HU P0301003 A HUP0301003 A HU P0301003A HU P0301003 A3 HUP0301003 A3 HU P0301003A3
Authority
HU
Hungary
Prior art keywords
therapy
derived peptides
casein derived
casein
peptides
Prior art date
Application number
HU0301003A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Peptera Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptera Pharmaceuticals Ltd filed Critical Peptera Pharmaceuticals Ltd
Publication of HUP0301003A2 publication Critical patent/HUP0301003A2/hu
Publication of HUP0301003A3 publication Critical patent/HUP0301003A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4732—Casein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
HU0301003A 2000-03-01 2001-03-01 Casein derived peptides and uses thereof in therapy HUP0301003A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL13483000A IL134830A0 (en) 2000-03-01 2000-03-01 Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
PCT/IL2001/000198 WO2001064234A1 (en) 2000-03-01 2001-03-01 Casein derived peptides and uses thereof in therapy

Publications (2)

Publication Number Publication Date
HUP0301003A2 HUP0301003A2 (hu) 2003-07-28
HUP0301003A3 true HUP0301003A3 (en) 2007-08-28

Family

ID=11073892

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301003A HUP0301003A3 (en) 2000-03-01 2001-03-01 Casein derived peptides and uses thereof in therapy

Country Status (21)

Country Link
US (6) US20020147144A1 (enExample)
EP (1) EP1261360B1 (enExample)
JP (1) JP2003528827A (enExample)
KR (1) KR20030025907A (enExample)
CN (1) CN1427725A (enExample)
AT (1) ATE451929T1 (enExample)
AU (1) AU782662B2 (enExample)
BR (1) BR0109027A (enExample)
CA (1) CA2401550A1 (enExample)
CZ (1) CZ20022915A3 (enExample)
DE (1) DE60140794D1 (enExample)
DK (1) DK1261360T3 (enExample)
EA (3) EA007217B1 (enExample)
HU (1) HUP0301003A3 (enExample)
IL (2) IL134830A0 (enExample)
MX (1) MXPA02008569A (enExample)
NO (1) NO20024157L (enExample)
NZ (1) NZ521016A (enExample)
PL (1) PL361307A1 (enExample)
WO (1) WO2001064234A1 (enExample)
ZA (1) ZA200206842B (enExample)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005511499A (ja) * 2001-08-30 2005-04-28 チャイ １３ メディカル リサーチ グループ エヌ． ヴイ． カゼイン由来ペプチドおよびその医療用途
AU2003217337A1 (en) * 2002-02-06 2003-09-02 University Of North Carolina At Chapel Hill High-throughput cell identification and isolation method and apparatus
EP1359157A1 (en) * 2002-04-29 2003-11-05 Société des Produits Nestlé S.A. Metallo-proteinase inhibitory agent
AU2003299568B2 (en) * 2002-11-27 2010-07-22 Ampio Pharmaceuticals, Inc. Treatment of diseases and conditions mediated by increased phosphorylation
GB0313892D0 (en) * 2003-06-16 2003-07-23 Hannah Res Inst Control of lactation
BRPI0507822A (pt) * 2004-03-01 2007-07-10 Peptera Pharmaceuticals Ltd método e composição farmacêutica para a prevenção ou o tratamento de uma doença ou uma condição autoimune ou infecciosa, método e composição farmacêutica para a prevenção ou o tratamento de uma doença ou uma condição do sangue, método e composição farmacêutica para modular a formação de células do sangue, método e composição farmacêutica para intensificar a mobilização periférico da célula tronco, método e composição farmacêutica para a prevenção ou o tratamento de uma doença ou uma condição metabólica, método e composição farmacêutica para a prevenção ou o tratamento das condições associadas com doses mieloablativas de quimioradioterapia suportadas pelo transplante autólogo de medula óssea ou de células tronco do sangue periférico (asct) ou pelo transplante alogenéico de medula óssea (bmt), método e composição farmacêutica para aumentar o efeito de um fator estimulante de células do sangue, método e composição farmacêutica para intensificar a colonização de células tronco do sangue doadas em um receptor mieloablatado, método e composição farmacêutica para a prevenção ou o tratamento de uma doença ou uma condição bacteriana, composição farmacêutica para o tratamento ou a prevenção de uma indicação selecionada do grupo que consiste em doença ou condição autoimune, doença viral, infecção viral, doença hematológica, deficiências hematológicas, trombocitopenia, pancitopenia, granulopenia, hiperlipidemia, hipercolesterolemia, glucosuria, hiperglicemia, diabetes, aids, hiv-1, distúrbios de células t auxiliares, deficiências de células dendrìticas, deficiências de macrofagos, distúrbios de células tronco hematopoiéticas incluindo distúrbios com plaquetas, linfócitos, células do plasma e neutrófilos, condições pré-leucêmicas, condições leucêmicas, distúrbios do sistema imunológico resultantes da terapia de quimioterapia ou de radiação, distúrbios do sistema imunológico humano resultantes do tratamento das doenças de deficiência imunológica e infecções bacterianas, composição farmacêutica para o tratamento ou a prevenção de um indicação selecionada do grupo que consiste em doença hematológica, deficiências hematológicas, trombocitopenia, pancitopenia, granulopenia, deficiências de células dendrìticas, deficiências de macrofagos, distúrbios de células tronco hematopoiéticas incluindo distúrbios com plaquetas, linfócitos, células do plasma e neutrófilos, condições pré-leucêmicas, condições leucêmicas, sìndrome mielodisplástiacas, malignidades não mielóides, anemia plástica e insuficiência da medula óssea, peptìdeo purificado, peptìdeo quimérico purificado, peptìdeo quimérico, composição farmacêutica, composição farmacêutica para a prevenção ou o tratamento de uma condição associada com um agente infeccioso de sars, método de processamento a baixa temperatura de hidrolisato proteolìtico de caseìna e hidrolisato de proteìna de caseìna
CA2561145C (en) 2004-03-30 2014-10-28 Monsanto Technology Llc Methods for controlling plant pathogens using n-phosphonomethylglycine
WO2005099724A2 (en) * 2004-04-13 2005-10-27 Parallel Solutions, Inc. Functionalized water-soluble polyphosphazene and uses thereof as modifiers of biological agents
WO2006036969A2 (en) 2004-09-28 2006-04-06 Atrium Medical Corporation Formation of barrier layer
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
GB0423352D0 (en) 2004-10-21 2004-11-24 Hannah Res Inst "Control of mammary cell number"
ES2400511T3 (es) * 2005-05-02 2013-04-10 Mileutis Ltd. Composiciones farmacéuticas que comprenden péptidos derivados de la caseina y métodos para el uso de las mismas
ES2319475B1 (es) * 2005-06-08 2010-02-16 Consejo Superior Investig. Cientificas Peptidos bioactivos identificados en hidrolizados enzimaticos de caseinas lacteas y procedimiento de obtencion.
US11266607B2 (en) * 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
EP2236608B1 (en) 2005-10-04 2016-12-07 Soligenix, Inc. Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
US20070086958A1 (en) * 2005-10-14 2007-04-19 Medafor, Incorporated Formation of medically useful gels comprising microporous particles and methods of use
GB2436328A (en) * 2006-03-22 2007-09-26 Regen Therapeutics Plc Peptide derived from colostrinin
EP1836906B1 (en) * 2006-03-24 2009-07-01 Unilever N.V. Healthy food product
BRPI0707042A2 (pt) * 2006-03-24 2011-04-12 Unilever Nv produto alimentìcio e uso
SG175573A1 (en) * 2006-10-04 2011-11-28 Inimex Pharmaceuticals Inc Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
ATE533353T1 (de) * 2007-02-05 2011-12-15 Univ Singapore Mutmasslicher cytokininrezeptor und verfahren für seine verwendung
US8097712B2 (en) 2007-11-07 2012-01-17 Beelogics Inc. Compositions for conferring tolerance to viral disease in social insects, and the use thereof
EP2255780A1 (en) * 2008-03-12 2010-12-01 Shiseido Company, Ltd. Parakeratosis inhibitor, pore shrinking agent or agent for preventing or improving rough skin, and composition for external use on the skin containing the same
CN102481233B (zh) * 2009-02-06 2014-07-30 宝洁公司 可崩解含水胶囊
CN102458112A (zh) * 2009-04-10 2012-05-16 阿布拉科斯生物科学有限公司 纳米颗粒制剂及其用途
CN103494765A (zh) 2009-05-04 2014-01-08 普西维达公司 多孔硅药物洗脱颗粒
US10555527B2 (en) * 2009-05-18 2020-02-11 Monsanto Technology Llc Use of glyphosate for disease suppression and yield enhancement in soybean
GB0912481D0 (en) 2009-07-17 2009-08-26 Reckitt Benckiser Healthcare I Skincare compositions
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
US8962584B2 (en) 2009-10-14 2015-02-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions for controlling Varroa mites in bees
EP2519214A4 (en) * 2009-12-29 2016-01-20 Grace W R & Co COMPOSITIONS FOR THE PREPARATION OF FILMS WITH DESIRED DEGREE OF DEGREE AND METHOD FOR THE PRODUCTION AND USE THEREOF
AU2011212859B2 (en) * 2010-02-04 2014-05-08 Isp Investments Inc. Self adapting polymers for anhydrous sunscreen formulations
CA2790029C (en) * 2010-02-18 2019-09-03 Athenix Corp. Axmi221z, axmi222z, axmi223z, axmi224z, and axmi225z delta-endotoxin genes and methods for their use
CN102892886A (zh) * 2010-02-18 2013-01-23 阿森尼克斯公司 AXMI218、AXMI219、AXMI220、AXMI226、AXMI227、AXMI228、AXMI229、AXMI230、和AXMI231δ-内毒素基因以及它们的使用方法
SG183407A1 (en) 2010-03-08 2012-09-27 Monsanto Technology Llc Polynucleotide molecules for gene regulation in plants
FR2958155B1 (fr) * 2010-04-02 2012-04-20 Oreal Composition de decoloration comprenant un sel peroxygene dans une base fortement riche en corps gras
WO2011137563A1 (en) * 2010-05-07 2011-11-10 Unilever Plc High solvent content emulsions
WO2011153186A1 (en) * 2010-06-04 2011-12-08 Monsanto Technology Llc Transgenic brassica event mon 88302 and methods of use thereof
EP2593141B1 (en) 2010-07-16 2018-07-04 Atrium Medical Corporation Composition and methods for altering the rate of hydrolysis of cured oil-based materials
MX2013001740A (es) * 2010-08-19 2013-05-20 Pioneer Hi Bred Int Nuevo gen de bacillus thuringiensis con actividad lepidoptera
US9757374B2 (en) 2010-10-28 2017-09-12 Aequus Pharmaceuticals Inc. Aripiprazole compositions and methods for its transdermal delivery
BR112013010190B1 (pt) * 2010-10-28 2019-12-31 Aequus Pharmaceuticals Inc composição farmacêutica
AU2011323524B2 (en) 2010-11-01 2016-12-08 Eyepoint Pharmaceuticals Us, Inc. Bioerodible silicon-based devices for delivery of therapeutic agents
CA2836911A1 (en) * 2011-06-04 2012-12-13 Ian S. CURTIS Potato transformation compositions, systems, methods, microorganisms, and plants
AU2012296987A1 (en) * 2011-08-12 2014-02-27 Bayer Cropscience Nv Guard cell-specific expression of transgenes in cotton
US10829828B2 (en) 2011-09-13 2020-11-10 Monsanto Technology Llc Methods and compositions for weed control
AU2012308694B2 (en) 2011-09-13 2018-06-14 Monsanto Technology Llc Methods and compositions for weed control
CA2848695A1 (en) 2011-09-13 2013-03-21 Monsanto Technology Llc Methods and composition for weed control comprising inhibiting ppg oxidase
CA2848680C (en) 2011-09-13 2020-05-19 Monsanto Technology Llc Methods and compositions for weed control
US10806146B2 (en) 2011-09-13 2020-10-20 Monsanto Technology Llc Methods and compositions for weed control
AU2012308686B2 (en) 2011-09-13 2018-05-10 Monsanto Technology Llc Methods and compositions for weed control
US10760086B2 (en) 2011-09-13 2020-09-01 Monsanto Technology Llc Methods and compositions for weed control
US9840715B1 (en) 2011-09-13 2017-12-12 Monsanto Technology Llc Methods and compositions for delaying senescence and improving disease tolerance and yield in plants
US9920326B1 (en) 2011-09-14 2018-03-20 Monsanto Technology Llc Methods and compositions for increasing invertase activity in plants
CN103842425B (zh) * 2011-10-05 2017-05-24 Fmc有限公司 微晶纤维素和羧甲基纤维素的稳定剂组合物、制备方法和应用
US9492363B1 (en) * 2012-01-16 2016-11-15 American Spraytech, L.L.C. Aerosol sprayable color composition
CA2861324A1 (en) * 2012-01-27 2013-08-01 Agile Therapeutics, Inc. Transdermal hormone delivery
FR2988566B1 (fr) * 2012-03-28 2014-08-08 Yoplait France Compositions alimentaires pour stimuler la formation de tissu osseux
CA2873828A1 (en) 2012-05-24 2013-11-28 A.B. Seeds Ltd. Naked dsrna for silencing target molecules in plant seeds
ES2942682T3 (es) * 2012-08-03 2023-06-05 Msm Innovations Inc Método y kit de preparación intestinal
US10273541B2 (en) 2012-08-14 2019-04-30 10X Genomics, Inc. Methods and systems for processing polynucleotides
CN111748607B (zh) 2012-08-14 2024-04-30 10X基因组学有限公司 微胶囊组合物及方法
US9701998B2 (en) 2012-12-14 2017-07-11 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10752949B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10221442B2 (en) 2012-08-14 2019-03-05 10X Genomics, Inc. Compositions and methods for sample processing
US11591637B2 (en) 2012-08-14 2023-02-28 10X Genomics, Inc. Compositions and methods for sample processing
US9951386B2 (en) 2014-06-26 2018-04-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10400280B2 (en) 2012-08-14 2019-09-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10323279B2 (en) 2012-08-14 2019-06-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9617297B2 (en) * 2012-10-11 2017-04-11 The Regents Of The University Of California Apoplast wash fluid recovery for improved recombinant endoglucanase extraction in tabacco leaves
MX364070B (es) 2012-10-18 2019-04-10 Monsanto Technology Llc Métodos y composiciones para el control de plagas vegetales.
US10533221B2 (en) 2012-12-14 2020-01-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
CA2894694C (en) 2012-12-14 2023-04-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9206436B2 (en) * 2012-12-20 2015-12-08 Ut-Battelle, Llc Key gene regulating cell wall biosynthesis and recalcitrance in Populus, gene Y
US10683505B2 (en) 2013-01-01 2020-06-16 Monsanto Technology Llc Methods of introducing dsRNA to plant seeds for modulating gene expression
EP2941487A2 (en) 2013-01-01 2015-11-11 A.B. Seeds Ltd. ISOLATED dsRNA MOLECULES AND METHODS OF USING SAME FOR SILENCING TARGET MOLECULES OF INTEREST
US10000767B2 (en) 2013-01-28 2018-06-19 Monsanto Technology Llc Methods and compositions for plant pest control
WO2014124338A1 (en) 2013-02-08 2014-08-14 10X Technologies, Inc. Polynucleotide barcode generation
US8961680B2 (en) * 2013-03-08 2015-02-24 Tbf Environmental Technology Inc. Solvent formulations
US20140271764A1 (en) * 2013-03-12 2014-09-18 Psivida Us, Inc. Bioerodible Silicon-Based Delivery Vehicles for Delivery of Therapeutic Agents
CN105263329B (zh) 2013-03-13 2020-09-18 孟山都技术公司 用于杂草控制的方法和组合物
CN105074008A (zh) 2013-03-13 2015-11-18 孟山都技术有限公司 用于杂草控制的方法和组合物
US20140283211A1 (en) 2013-03-14 2014-09-18 Monsanto Technology Llc Methods and Compositions for Plant Pest Control
US10568328B2 (en) 2013-03-15 2020-02-25 Monsanto Technology Llc Methods and compositions for weed control
HK1216720A1 (zh) 2013-03-15 2016-12-02 Psi医疗有限公司 用於递送治疗剂的可生物蚀解的硅基组合物
US9345727B2 (en) 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component and uses thereof
US9138455B2 (en) 2013-03-15 2015-09-22 Mead Johnson Nutrition Company Activating adiponectin by casein hydrolysate
US8889633B2 (en) 2013-03-15 2014-11-18 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof
US9345741B2 (en) 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof
US9289461B2 (en) * 2013-03-15 2016-03-22 Mead Johnson Nutrition Company Reducing the risk of autoimmune disease
US9352020B2 (en) 2013-03-15 2016-05-31 Mead Johnson Nutrition Company Reducing proinflammatory response
DK2968099T3 (da) * 2013-03-15 2020-07-20 Maria Beug Deeb Inc Dba T&M Ass Metoder og sammensætninger til rengøring og desinfektion af overflader
CA2817728A1 (en) * 2013-05-31 2014-11-30 Pharmascience Inc. Abuse deterrent immediate release formulation
US9850496B2 (en) 2013-07-19 2017-12-26 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
UA122662C2 (uk) 2013-07-19 2020-12-28 Монсанто Текнолоджі Ллс Композиція та спосіб боротьби з leptinotarsa
ES2693580T3 (es) * 2013-10-07 2018-12-12 Bristol-Myers Squibb Holdings Ireland Formulación de tratamiento del VIH de atazanavir y cobicistat
RU2694950C2 (ru) 2013-11-04 2019-07-18 Монсанто Текнолоджи Ллс Композиции и способы для борьбы с членистоногими паразитами и заражениями вредителями
UA119253C2 (uk) 2013-12-10 2019-05-27 Біолоджикс, Інк. Спосіб боротьби із вірусом у кліща varroa та у бджіл
WO2015108982A2 (en) 2014-01-15 2015-07-23 Monsanto Technology Llc Methods and compositions for weed control using epsps polynucleotides
ES2544153B1 (es) * 2014-02-24 2016-06-06 Ntd Labs, S.L. Uso de un hidrolizado de caseína como agente antiviral
CN106413390B (zh) 2014-04-01 2019-09-27 孟山都技术公司 用于控制虫害的组合物和方法
CN114534806B (zh) 2014-04-10 2024-03-29 10X基因组学有限公司 用于封装和分割试剂的流体装置、系统和方法及其应用
CA2953347A1 (en) 2014-06-23 2015-12-30 Monsanto Technology Llc Compositions and methods for regulating gene expression via rna interference
US11807857B2 (en) 2014-06-25 2023-11-07 Monsanto Technology Llc Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
US12312640B2 (en) 2014-06-26 2025-05-27 10X Genomics, Inc. Analysis of nucleic acid sequences
CN106536756A (zh) 2014-06-26 2017-03-22 10X基因组学有限公司 核酸序列的分析
CN113249435B (zh) 2014-06-26 2024-09-03 10X基因组学有限公司 分析来自单个细胞或细胞群体的核酸的方法
EP3167049A4 (en) 2014-07-08 2017-11-29 MIMEDX Group Inc. Micronized wharton's jelly
US20160022604A1 (en) * 2014-07-23 2016-01-28 Cadila Healthcare Limited Directly compressed ospemifene compositions
RU2021123470A (ru) 2014-07-29 2021-09-06 Монсанто Текнолоджи Ллс Композиции и способы борьбы с насекомыми-вредителями
PL3191083T3 (pl) * 2014-09-11 2021-07-12 Gelita Ag Cząstki żelatyny/pektyny
CN116195595A (zh) 2014-09-17 2023-06-02 阿萨达有限责任公司 活化的过氧化氢消毒组合物
CN114807307A (zh) 2014-10-29 2022-07-29 10X 基因组学有限公司 用于靶核酸测序的方法和组合物
US9975122B2 (en) 2014-11-05 2018-05-22 10X Genomics, Inc. Instrument systems for integrated sample processing
WO2016111285A1 (ja) * 2015-01-06 2016-07-14 山田　修 燃焼合成材料を利用した医薬組成物、血液処理装置、化粧料及び飲食品
SG11201705615UA (en) 2015-01-12 2017-08-30 10X Genomics Inc Processes and systems for preparing nucleic acid sequencing libraries and libraries prepared using same
JP6942632B2 (ja) 2015-01-22 2021-09-29 モンサント テクノロジー エルエルシー Ｌｅｐｔｉｎｏｔａｒｓａ防除用組成物及びその方法
WO2016137973A1 (en) 2015-02-24 2016-09-01 10X Genomics Inc Partition processing methods and systems
US11274343B2 (en) 2015-02-24 2022-03-15 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequence coverage
CA2977961A1 (en) 2015-02-25 2016-09-01 The Procter & Gamble Company Fibrous structures comprising a surface softening composition
US20160303043A1 (en) * 2015-04-16 2016-10-20 Kate Somerville Skincare, LLC Self-foaming compositions and methods
UY36703A (es) 2015-06-02 2016-12-30 Monsanto Technology Llc Composiciones y métodos para la administración de un polinucleótido en una planta
WO2016196782A1 (en) 2015-06-03 2016-12-08 Monsanto Technology Llc Methods and compositions for introducing nucleic acids into plants
CN107849825A (zh) 2015-07-10 2018-03-27 宝洁公司 包含复分解不饱和多元醇酯的织物护理组合物
SG11201804086VA (en) 2015-12-04 2018-06-28 10X Genomics Inc Methods and compositions for nucleic acid analysis
WO2017197343A2 (en) 2016-05-12 2017-11-16 10X Genomics, Inc. Microfluidic on-chip filters
WO2017197338A1 (en) 2016-05-13 2017-11-16 10X Genomics, Inc. Microfluidic systems and methods of use
BR112019000371A2 (pt) * 2016-07-08 2019-04-24 The Gillette Company Llc composições líquidas para dispositivos de remoção de pelos que compreendem ésteres de poliol insaturados metatetizados
DE102016223333A1 (de) * 2016-11-24 2018-05-24 Henkel Ag & Co. Kgaa Alkalische Mittel zum Aufhellen von Haaren enthaltend Oxidationsmittel und spezielle Carbonsäureester als Keratinvernetzer
US10011872B1 (en) 2016-12-22 2018-07-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10815525B2 (en) 2016-12-22 2020-10-27 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10550429B2 (en) 2016-12-22 2020-02-04 10X Genomics, Inc. Methods and systems for processing polynucleotides
US12264411B2 (en) 2017-01-30 2025-04-01 10X Genomics, Inc. Methods and systems for analysis
EP3545089B1 (en) 2017-01-30 2022-03-09 10X Genomics, Inc. Methods and systems for droplet-based single cell barcoding
WO2018160882A1 (en) 2017-03-01 2018-09-07 Arena Pharmaceuticals, Inc. Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
US10398670B2 (en) * 2017-04-24 2019-09-03 Knoze Jr. Corporation Oral microbiota promotion for oral and/or sinus infections
CN116064732A (zh) 2017-05-26 2023-05-05 10X基因组学有限公司 转座酶可接近性染色质的单细胞分析
US20180340169A1 (en) 2017-05-26 2018-11-29 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US10471033B2 (en) * 2017-09-15 2019-11-12 Knoze Jr. Corporation Oral microbiota promotion for immune system associated inflammations
US12151014B2 (en) * 2017-09-18 2024-11-26 Mast Industries (Far East) Limited Gloss lip balm formulation
CN111051523B (zh) 2017-11-15 2024-03-19 10X基因组学有限公司 功能化凝胶珠
US10829815B2 (en) 2017-11-17 2020-11-10 10X Genomics, Inc. Methods and systems for associating physical and genetic properties of biological particles
SG11202009889VA (en) 2018-04-06 2020-11-27 10X Genomics Inc Systems and methods for quality control in single cell processing
BR112022004757A2 (pt) * 2019-09-16 2022-06-21 Kiverdi Inc Composições de hidrolizado de proteína microbiana e métodos para fazer as mesmas

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3764670A (en) * 1970-10-28 1973-10-09 Ministry Of Agriculture Polypeptidic anti-biotic substances derived from casein
US3778426A (en) * 1970-12-16 1973-12-11 Research Corp Therapeutically useful polypeptides
US4636384A (en) * 1982-06-03 1987-01-13 Stolle Research & Development Corporation Method for treating disorders of the vascular and pulmonary systems
US4959455A (en) * 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5344820A (en) * 1987-05-15 1994-09-06 Snow Brand Milk Products Co., Ltd. Infection protectant
JP2631470B2 (ja) * 1987-05-15 1997-07-16 雪印乳業株式会社 感染防御剤
JP2805490B2 (ja) * 1989-02-07 1998-09-30 雪印乳業株式会社 細菌毒素中和剤
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
FR2686085B1 (fr) * 1992-01-10 1995-08-04 Agronomique Inst Nat Rech Peptides representant des fragments du cmp, anticorps diriges contre lesdits peptides, et leurs utilisations.
GB9310472D0 (en) * 1993-05-20 1993-07-07 Univ Warwick Phenylalanine-free protein and dna coding thereof
TW282398B (enExample) * 1993-12-22 1996-08-01 Bristol Myers Squibb Co
US5538952A (en) * 1994-05-26 1996-07-23 Abbott Laboratories Inhibition of infection of mammalian cells by respiratory syncytial virus
US5707968A (en) * 1994-05-26 1998-01-13 Abbott Laboratories Inhibition of attachment of H.influenzae to human cells
US5506209A (en) * 1994-05-26 1996-04-09 Abbott Laboratories Product for inhibition of infection of mammalian cells by respiratory syncytial virus
US5712250A (en) * 1994-09-16 1998-01-27 Abbott Laboratories Product for inhibition of human rotavirus infection
KR0140248B1 (ko) * 1995-03-23 1998-06-15 한상기 신규한 카제인 포스포펩티드, 그것을 포함하는 카제인 및 그 제조방법
US5985275A (en) * 1995-04-12 1999-11-16 New York Blood Center β-Lactoglobulin modified with aromatic anhydride compound for preventing HIV infection
US6570060B2 (en) * 1995-05-16 2003-05-27 Mclachlan Corran Norman Stuart Milk lacking β-casein A1
KR100221124B1 (ko) * 1996-09-23 1999-10-01 한상기 신규한 카제인 및 그 제조방법
US5830434A (en) * 1997-02-26 1998-11-03 Medical University Of South Carolina Foundation For Research Development Methods of treating non-insulin dependent diabetes mellitus with pancreatic polypeptide
NZ332993A (en) * 1997-03-21 2000-01-28 Snow Brand Milk Products Co Ltd Iron-casein complex hydrolyzate and process for the production thereof
US6358508B1 (en) * 1997-06-11 2002-03-19 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR9
JP4459435B2 (ja) * 1997-08-29 2010-04-28 ナラン ウトゥク 新規ｔ細胞膜蛋白質（ｔｉｒｃ７）、ペプチドおよびそれに由来する抗体ならびにその使用
AUPP051497A0 (en) * 1997-11-24 1997-12-18 University Of Melbourne, The Antimicrobial peptides
US5985575A (en) * 1998-05-20 1999-11-16 Wisconsin Alumni Research Foundation Tethered function assay for protein function
US6570606B1 (en) * 1998-05-29 2003-05-27 3Com Corporation Method and apparatus for controlling transmission of media signals over a data network in response to triggering events at participating stations
CA2350911A1 (en) * 1998-11-16 2000-05-25 Board Of Regents, The University Of Texas System Hiv-specific t-cell induction
GB9927603D0 (en) * 1999-11-22 2000-01-19 Nestle Sa Use of a milk protein hydrolysate in the treatment of diabetes
IL138946A0 (en) * 2000-10-11 2001-11-25 Compugen Ltd Method for the identification of peptides and proteins
JP2009511435A (ja) * 2005-09-28 2009-03-19 ディーエヌピー・カナダ・インコーポレーテッド 高脂血症の予防および治療のためのポリキトサミンとフィブレートの組み合わせ
US8865876B2 (en) * 2008-06-02 2014-10-21 California Institute Of Technology Engineered lectin oligomers with antiviral activity

Also Published As

Publication number Publication date
ATE451929T1 (de) 2010-01-15
DE60140794D1 (de) 2010-01-28
WO2001064234A1 (en) 2001-09-07
EA200401467A1 (ru) 2005-04-28
US7741274B2 (en) 2010-06-22
KR20030025907A (ko) 2003-03-29
IL151351A (en) 2012-04-30
CN1427725A (zh) 2003-07-02
US20090192081A1 (en) 2009-07-30
EA200400376A1 (ru) 2005-06-30
IL134830A0 (en) 2001-05-20
CZ20022915A3 (cs) 2003-03-12
CA2401550A1 (en) 2001-09-07
EA007814B1 (ru) 2007-02-27
HUP0301003A2 (hu) 2003-07-28
AU782662B2 (en) 2005-08-18
EA200200820A1 (ru) 2003-08-28
PL361307A1 (en) 2004-10-04
EA005579B1 (ru) 2005-04-28
US20020147144A1 (en) 2002-10-10
NO20024157L (no) 2002-10-30
NZ521016A (en) 2005-08-26
US8735348B2 (en) 2014-05-27
JP2003528827A (ja) 2003-09-30
ZA200206842B (en) 2003-07-28
EA007217B1 (ru) 2006-08-25
NO20024157D0 (no) 2002-08-30
DK1261360T3 (da) 2010-05-03
US20100317601A1 (en) 2010-12-16
MXPA02008569A (es) 2003-02-24
EP1261360B1 (en) 2009-12-16
US20100298216A1 (en) 2010-11-25
US20130096073A1 (en) 2013-04-18
BR0109027A (pt) 2003-06-03
EP1261360A4 (en) 2004-03-10
US20070161557A1 (en) 2007-07-12
AU3596201A (en) 2001-09-12
EP1261360A1 (en) 2002-12-04

Similar Documents

Publication Publication Date Title
HUP0301003A3 (en) Casein derived peptides and uses thereof in therapy
TWI317737B (en) Membrane penetrating peptides and uses thereof
IL153970A0 (en) Promyostatin peptides and methods of using same
PL346346A1 (en) Cyclic prosaposin-derived peptides and uses thereof
AU2002365396A8 (en) Peptides, peptide compositions,and methods of use in binding p 185
EP1414848A4 (en) REPLICINE PEPTIDES AND ITS USES
GB9806806D0 (en) Peptides and uses thereof
HUP0500995A3 (en) Casein derived peptides and uses thereof in therapy
SI1462455T1 (sl) Ser-Ser-Ser-Arg Peptid in zdravilna uporaba le-tega
EP1419175A4 (en) PEPTIDES OF REPLIKIN AND THEIR USE
AU2001266229A1 (en) Hcn polypeptides and polynucleotides and their use in therapy
IL131707A0 (en) Acetylcholinesterase-derived peptides and uses thereof
EP1343819A4 (en) HLA-A2.1 BINDING SPEPTIDES AND THEIR USE
GB9918155D0 (en) Proteins and peptides
GB0026134D0 (en) Peptides and their use
IL131719A0 (en) Iren protein its preparation and use
EP1080185A4 (en) BASIC PROTEIN PEPTIDES OF MYELIN AND THE USE THEREOF.
IL151351A0 (en) Casein derived peptides and uses thereof in therapy
IL144225A0 (en) ((aminoiminomethyl) amino) alkanecarboxamides and their applications in therapy
HK1051501A (en) Casein derived peptides and uses thereof in therapy
GB0017028D0 (en) Peptides and their therapeutic use
EP1300416A4 (en) PEPTIDE FOR INCREASING THE MEMORY AND ITS APPLICATIONS
GB0018148D0 (en) Peptides and their use
GB0026135D0 (en) Peptides and their use
GB0026136D0 (en) Peptides and their use

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: PEPTERA PHARMACEUTICALS LTD., IL

Free format text: FORMER OWNER(S): CHAY 13 MEDICAL RESEARCH GROUP N.V., NL

FD9A Lapse of provisional protection due to non-payment of fees